비교

Stem Cell Breast Augmentation vs SVF Breast Augmentation

아래 사실은 모두 두 엔티티 페이지와 그 출처에서 가져온 것입니다. 양쪽이 함께 기록한 항목을 먼저 대조하고, 나머지는 나란히 보여 줍니다.

Stem Cell Breast AugmentationA consumer and marketing term for breast fat grafting enriched with stromal vascular fraction or adipose-derived cells. It is not a separate regulated procedure category.갱신 2026년 9월 21일

의료

SVF Breast AugmentationSVF breast augmentation is breast fat grafting in which the injected fat is enriched with the patient's own stromal vascular fraction.갱신 2026년 9월 21일

둘의 관계Stem Cell Breast Augmentation — 흔히 가리키는 시술 → SVF Breast Augmentation

공통 항목

양쪽 모두 기록된 항목 0개

두 항목이 공통으로 기록한 항목이 아직 없습니다. 각각의 검증된 사실은 아래에 있습니다.

각각의 사실

둘 중 한쪽에만 기록된 검증된 사실입니다.

Stem Cell Breast Augmentation

아직 검증된 값이 없습니다

SVF Breast Augmentation

DefinitionAutologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat

First described for cosmetic breast augmentationYoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL

Complications in original seriesCysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis

Breast augmentation meta-analysis (Li & Chen)6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference

Meta-analysis across recipient sites (Sutar et al.)15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent

US FDA positionAdipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic

US court ruling on same-day SVFNinth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15

Korea: Advanced Regenerative Bio Act amendmentEffective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans

Reported safety concernsCyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient

Method standardizationNo standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem)

Reported outcome (SC301-authored, 2023)Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102)

Reported outcome (SC301-authored, 2020)In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million

Evidence levelSingle-center, provider-authored series; no independent randomized controlled data identified as of 2026-09